Financial

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of...

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentationCAMBRIDGE, Mass., Sept. 16, 2022...

Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome

Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteinsREDWOOD...

H1 Launches AI-Powered and Evidence-Based Interactions to Meet the Evolving Needs of Pharmaceutical and Biotech Medical Affairs Teams

New capabilities within H1’s HCP Universe platform empower corporate Medical Affairs and MSL teams to act faster and more effectively...

error: Content is protected !!